関連する実験動画

Updated: Jul 5, 2026

Imaging Cleared Intact Biological Systems at a Cellular Level by 3DISCO
07:49

Imaging Cleared Intact Biological Systems at a Cellular Level by 3DISCO

Published on: July 7, 2014

ICRF:混乱からメルトダウンへ. 帝国のがん研究基金

R Horton1

  • 1The Lancet, London, UK.

Lancet (London, England)
|April 23, 1999
PubMed
まとめ

No abstract available in PubMed .

キーワード:
生物医学および行動研究帝国のがん研究基金ランセット Lancetはランセット誌に掲載されています.

さらに関連する動画

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

関連する概念動画

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...